BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC

Affiliations

¹ Yale Cancer Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
² Yale Cancer Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. Roy.Herbst@yale.edu.

Comment

So Yeon Kim et al. Nat Rev Clin Oncol. 2023 Jan.

. 2023 Jan;20(1):3-4.

doi: 10.1038/s41571-022-00698-y.

¹ Yale Cancer Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
² Yale Cancer Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. Roy.Herbst@yale.edu.

No abstract available

Comment on

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.

1. Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019). - DOI
1. Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017). - DOI
1. Kim, E. S. et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat. Med. 28, 939–945 (2022). - DOI
1. Herbst, R. S. et al. Atezolizumab for first-Line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med. 383, 1328–1339 (2020). - DOI
1. Peters, S. et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat. Med. 28, 1831–1839 (2022). - DOI